Cargando…

Efficacy of ARV-1502, a Proline-Rich Antimicrobial Peptide, in a Murine Model of Bacteremia Caused by Multi-Drug Resistant (MDR) Acinetobacter baumannii

Acinetobacter baumannii bacteremia represents a serious and increasing clinical problem due to the high mortality and treatment failures because of high rates of antibiotic resistance. Any additional new therapies for A. baumannii bacteremia would address a growing unmet medical need. ARV-1502 (desi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiong, Yan Q., Li, Liang, Zhou, Yufeng, Kraus, Carl N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696424/ https://www.ncbi.nlm.nih.gov/pubmed/31382389 http://dx.doi.org/10.3390/molecules24152820

Ejemplares similares

Influence of Substitutions in the Binding Motif of Proline-Rich Antimicrobial Peptide ARV-1502 on 70S Ribosome Binding and Antimicrobial Activity
por: Brakel, Alexandra, et al.
Publicado: (2022)

Functional Effects of ARV-1502 Analogs Against Bacterial Hsp70 and Implications for Antimicrobial Activity
por: Brakel, Alexandra, et al.
Publicado: (2022)

Quantitation of a Novel Engineered Anti-infective Host Defense Peptide, ARV-1502: Pharmacokinetic Study of Different Doses in Rats and Dogs
por: Brakel, Alexandra, et al.
Publicado: (2019)

Evolution of Acinetobacter baumannii in Clinical Bacteremia Patients
por: Li, Henan, et al.
Publicado: (2021)

Is Polymicrobial Bacteremia an Independent Risk Factor for Mortality in Acinetobacter baumannii Bacteremia?
por: Wang, Yung-Chih, et al.
Publicado: (2020)

Risk Factors for Mortality in Patients with Acinetobacter baumannii Bacteremia
por: Park, Se Yoon, et al.
Publicado: (2013)

Initial indicators for the prognosis of Acinetobacter Baumannii bacteremia in children
por: Hong, Yi, et al.
Publicado: (2023)

In vivo bactericidal effect of colistin–linezolid combination in a murine model of MDR and XDR Acinetobacter baumannii pneumonia
por: Ma, Xiao-Lin, et al.
Publicado: (2020)

Virulence Potential and Treatment Options of Multidrug-Resistant (MDR) Acinetobacter baumannii
por: Kumar, Sunil, et al.
Publicado: (2021)

Comparison between bacteremia caused by carbapenem resistant Acinetobacter baumannii and Acinetobacter nosocomialis
por: Yang, Ya-Sung, et al.
Publicado: (2013)

Using WGS to identify antibiotic resistance genes and predict antimicrobial resistance phenotypes in MDR Acinetobacter baumannii in Tanzania
por: Kumburu, Happiness H, et al.
Publicado: (2019)

Evaluation of outcome in critically ill patients with Acinetobacter baumannii bacteremia
por: Pratikaki, M, et al.
Publicado: (2005)

Risk Factors and Clinical Outcomes for Patients With Acinetobacter baumannii Bacteremia
por: Gu, Zhenyang, et al.
Publicado: (2016)

Risk Factors, Clinical Presentation, and Outcome of Acinetobacter baumannii Bacteremia
por: Ballouz, Tala, et al.
Publicado: (2017)

A case of disseminated intravascular coagulation secondary to Acinetobacter lwoffii and Acinetobacter baumannii bacteremia
por: Baldeo, Candice, et al.
Publicado: (2015)

Risk Factors and Drug Resistance of the MDR Acinetobacter Baumannii in Pneumonia Patients in ICU
por: Ren, Jichen, et al.
Publicado: (2019)

Computationally Designed AMPs with Antibacterial and Antibiofilm Activity against MDR Acinetobacter baumannii
por: Alsaab, Fahad M., et al.
Publicado: (2023)

Risk Factors for Mortality in Patients with Carbapenem-Resistant Acinetobacter baumannii Bacteremia: Impact of Appropriate Antimicrobial Therapy
por: Kim, Youn Jeong, et al.
Publicado: (2012)

Tryptophan-Rich and Proline-Rich Antimicrobial Peptides
por: Mishra, Awdhesh Kumar, et al.
Publicado: (2018)

Proline‐Rich Peptides with Improved Antimicrobial Activity against E. coli, K. pneumoniae, and A. baumannii
por: Mardirossian, Mario, et al.
Publicado: (2019)

Acinetobacter baumannii bacteremia, a rare complication of endoscopic retrograde cholagiopancreatography!
por: Jabri, Hadoun, et al.
Publicado: (2014)

Bacteremia by colistin-resistant Acinetobacter baumannii isolate: a case report
por: Garcia Casallas, Julio Cesar, et al.
Publicado: (2019)

Colistin Resistance in Acinetobacter baumannii MDR-ZJ06 Revealed by a Multiomics Approach
por: Hua, Xiaoting, et al.
Publicado: (2017)

Theoretical and Experimental Studies of Phosphonium Ionic Liquids as Potential Antibacterials of MDR Acinetobacter baumannii
por: Metelytsia, Larysa O., et al.
Publicado: (2022)

Differential Gene Expression of Efflux Pumps and Porins in Clinical Isolates of MDR Acinetobacter baumannii
por: AlQumaizi, Khalid I., et al.
Publicado: (2022)

Biofilm formation is not an independent risk factor for mortality in patients with Acinetobacter baumannii bacteremia
por: Chiang, Tsung-Ta, et al.
Publicado: (2022)

715. Bulgecin A lowers Imipenem MICs in Clinical MDR Acinetobacter baumannii (ACB) Strains
por: Skalweit, Marion J, et al.
Publicado: (2019)

Drugs with new lease of life as quorum sensing inhibitors: for combating MDR Acinetobacter baumannii infections
por: Seleem, Noura M., et al.
Publicado: (2020)

Computational screening of antimicrobial peptides for Acinetobacter baumannii
por: Majumder, Ayan, et al.
Publicado: (2019)

Colistin-Resistant Acinetobacter Baumannii Bacteremia: A Serious Threat for Critically Ill Patients
por: Papathanakos, Georgios, et al.
Publicado: (2020)

1824. Combination therapy of daptomycin/colistin for extreme drug resistant Acinetobacter baumannii bacteremia
por: Lampada, Charis, et al.
Publicado: (2022)

1855. Risk factors for early mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia
por: Lee, Chan Mi, et al.
Publicado: (2022)

Community acquired multi drug resistant (MDR) Acinetobacter baumannii pneumonia in Malaysia – A case report
por: Mohd, Rozita, et al.
Publicado: (2018)

Immunoprotective potential of BamA, the outer membrane protein assembly factor, against MDR Acinetobacter baumannii
por: Singh, Ravinder, et al.
Publicado: (2017)

Colonization of long term care facility patients with MDR-Gram-negatives during an Acinetobacter baumannii outbreak
por: Zollner-Schwetz, Ines, et al.
Publicado: (2017)

DksA Modulates Antimicrobial Susceptibility of Acinetobacter baumannii
por: Kim, Nayeong, et al.
Publicado: (2021)

O047: The effect of active surveillance culture of carbapenem resistant Acinetobacter baumannii on the occurrence of carbapenem resistant Acinetobacter baumannii bacteremia in a single intensive care unit
por: Kim, G, et al.
Publicado: (2013)

Characterization of Two Novel Bacteriophages Infecting Multidrug-Resistant (MDR) Acinetobacter baumannii and Evaluation of Their Therapeutic Efficacy in Vivo
por: Cha, Kyoungeun, et al.
Publicado: (2018)

Pharmacokinetic-pharmacodynamic modelling to investigate in vitro synergy between colistin and fusidic acid against MDR Acinetobacter baumannii
por: Phee, Lynette M, et al.
Publicado: (2019)

CLSI based antibiogram profile and the detection of MDR and XDR strains of Acinetobacter baumannii isolated from urine samples
por: Girija AS, Smiline, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ajc8comam8svg2ln656ku1eoab